By enhancing glucose-dependent insulin secretion and suppressing glucagon release, these agents reduce chronic hyperglycemia-induced oxidative stress and AGE accumulation, thereby attenuating glomerular basement membrane thickening and albuminuria (100). This evidence concerns the gene INS and Hyperglycemia.